Envista Holdings Corporation (NYSE:NVST – Free Report) – Equities research analysts at Leerink Partnrs raised their FY2026 earnings estimates for shares of Envista in a research note issued on Tuesday, October 14th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $1.21 per share for the year, up from their previous estimate of $1.14. The consensus estimate for Envista’s current full-year earnings is $1.00 per share. Leerink Partnrs also issued estimates for Envista’s FY2027 earnings at $1.45 EPS and FY2028 earnings at $1.63 EPS.
Envista (NYSE:NVST – Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.84%. The business had revenue of $682.10 million during the quarter, compared to the consensus estimate of $638.21 million. During the same period in the previous year, the firm posted $0.11 earnings per share. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. Envista has set its FY 2025 guidance at 1.050-1.15 EPS.
Read Our Latest Research Report on Envista
Envista Stock Up 0.7%
Envista stock opened at $19.58 on Wednesday. The business’s 50-day simple moving average is $20.67 and its two-hundred day simple moving average is $19.00. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.08 and a current ratio of 2.44. The company has a market cap of $3.25 billion, a PE ratio of 61.20, a PEG ratio of 1.04 and a beta of 1.01. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00.
Institutional Investors Weigh In On Envista
Several hedge funds have recently modified their holdings of NVST. Farther Finance Advisors LLC grew its position in shares of Envista by 317.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock valued at $27,000 after acquiring an additional 1,026 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after purchasing an additional 949 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after purchasing an additional 1,909 shares during the period. GAMMA Investing LLC increased its position in shares of Envista by 34.3% in the third quarter. GAMMA Investing LLC now owns 2,498 shares of the company’s stock valued at $51,000 after buying an additional 638 shares in the last quarter. Finally, Parallel Advisors LLC raised its stake in shares of Envista by 100.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after buying an additional 1,397 shares during the period.
About Envista
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
- Five stocks we like better than Envista
- How is Compound Interest Calculated?
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- Are Penny Stocks a Good Fit for Your Portfolio?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- What Are Dividend Champions? How to Invest in the Champions
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.